Trials / Terminated
TerminatedNCT02318914
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gevokizumab |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-02-01
- Completion
- 2016-02-01
- First posted
- 2014-12-17
- Last updated
- 2016-04-27
Locations
40 sites across 3 countries: United States, Australia, Canada
Source: ClinicalTrials.gov record NCT02318914. Inclusion in this directory is not an endorsement.